Diabetic Nephropathy, Type 2 Diabetes Mellitus
Conditions
Brief summary
The purpose of this study is to evaluate the effect of treatment with CCX140-B on urinary albumin excretion in subjects with type 2 diabetes mellitus and albuminuria, as well as to study the safety and efficacy of the medication in this patient population.
Detailed description
Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.
Interventions
DRUGPlacebo
Placebo capsules once daily
DRUGCCX140-B
CCX140-B capsules once daily (Group B)
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Aged 18-75 years inclusive, with documented previously diagnosed type 2 diabetes mellitus (per American Diabetes Association \[ADA\] criteria), and treated with oral antidiabetic drugs * Albumin:creatinine ratio (ACR) of 200 to 3000 mg/g creatinine, inclusive, based on two values obtained from two first morning urine samples taken on two separate days during the screening period * Estimated glomerular filtration rate based on serum creatinine (eGFR, determined by Modification of Diet in Renal Disease \[MDRD\] equation) of ≥ 25 mL/min/1.73 m(2) * Must be on a stable dose of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) for at least 8 weeks prior to screening * Fasting plasma glucose less than 270 mg/dL at screening Key
Exclusion criteria
* Type 1 diabetes mellitus or history of diabetic ketoacidosis * Previous renal transplant or known non-diabetic renal disease, except related to hypertension * Undergone renal dialysis at any time in the past * Received chronic (more than 7 days continuously) systemic glucocorticoid or other immunosuppressive treatment within 8 weeks of screening * Use of bardoxolone, atrasentan or other endothelin antagonist within 8 weeks of screening * Received chronic (more than 7 days continuously) non-steroidal anti-inflammatory drug (NSAID) treatment within 2 weeks of screening * Cardiac failure (class III or IV), history of unstable angina, symptomatic coronary artery disease, myocardial infarction or stroke within 12 weeks of screening * Poorly-controlled blood pressure (systolic blood pressure \>155 or diastolic blood pressure \>95, with blood pressure measured in the seated position after at least 5 minutes of rest)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in 24-hour urinary albumin excretion | 84 days | The primary efficacy objective of this study is to evaluate the effect of CCX140-B treatment on urinary albumin excretion by measuring change from baseline in 24-hour urinary albumin excretion. |
| Subject incidence of adverse events | 84 days | The primary safety objective of this study is to evaluate the safety and tolerability of CCX140-B in subjects with type 2 diabetes mellitus (T2DM) with albuminuria. |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in hemoglobin A1c | 84 days |
Countries
Netherlands
Outcome results
None listed